Financhill
Sell
48

VNDA Quote, Financials, Valuation and Earnings

Last price:
$4.89
Seasonality move :
-7.11%
Day range:
$4.70 - $4.90
52-week range:
$3.81 - $6.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.36x
P/B ratio:
0.54x
Volume:
335.6K
Avg. volume:
403.2K
1-year change:
-16.13%
Market cap:
$275.8M
Revenue:
$198.8M
EPS (TTM):
-$0.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VNDA
Vanda Pharmaceuticals
$54.8M -- 8.51% -- $12.67
ADVM
Adverum Biotechnologies
-- -$2.28 -97.98% -157.58% $19.75
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VNDA
Vanda Pharmaceuticals
$4.68 $12.67 $275.8M -- $0.00 0% 1.36x
ADVM
Adverum Biotechnologies
$2.26 $19.75 $47.2M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.61 $0.85 $3.5M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.40 -- $22.5M -- $0.00 0% --
OGEN
Oragenics
$1.55 $1.00 $1.1M -- $0.00 0% 0.50x
TOVX
Theriva Biologics
$0.44 $7.00 $3.6M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VNDA
Vanda Pharmaceuticals
-- 0.464 -- 3.71x
ADVM
Adverum Biotechnologies
-- -0.484 -- 5.54x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VNDA
Vanda Pharmaceuticals
$46.5M -$41M -8.26% -8.26% -81.99% -$33.6M
ADVM
Adverum Biotechnologies
-- -$48.2M -69.14% -69.14% -2922.1% -$43M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Vanda Pharmaceuticals vs. Competitors

  • Which has Higher Returns VNDA or ADVM?

    Adverum Biotechnologies has a net margin of -58.94% compared to Vanda Pharmaceuticals's net margin of -2713.4%. Vanda Pharmaceuticals's return on equity of -8.26% beat Adverum Biotechnologies's return on equity of -69.14%.

    Company Gross Margin Earnings Per Share Invested Capital
    VNDA
    Vanda Pharmaceuticals
    92.96% -$0.50 $511.4M
    ADVM
    Adverum Biotechnologies
    -- -$2.25 $144.1M
  • What do Analysts Say About VNDA or ADVM?

    Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 170.66%. On the other hand Adverum Biotechnologies has an analysts' consensus of $19.75 which suggests that it could grow by 773.89%. Given that Adverum Biotechnologies has higher upside potential than Vanda Pharmaceuticals, analysts believe Adverum Biotechnologies is more attractive than Vanda Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VNDA
    Vanda Pharmaceuticals
    1 1 0
    ADVM
    Adverum Biotechnologies
    4 1 0
  • Is VNDA or ADVM More Risky?

    Vanda Pharmaceuticals has a beta of 0.683, which suggesting that the stock is 31.678% less volatile than S&P 500. In comparison Adverum Biotechnologies has a beta of 0.701, suggesting its less volatile than the S&P 500 by 29.914%.

  • Which is a Better Dividend Stock VNDA or ADVM?

    Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adverum Biotechnologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Adverum Biotechnologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VNDA or ADVM?

    Vanda Pharmaceuticals quarterly revenues are $50M, which are larger than Adverum Biotechnologies quarterly revenues of $1M. Vanda Pharmaceuticals's net income of -$29.5M is higher than Adverum Biotechnologies's net income of -$47M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Adverum Biotechnologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.36x versus -- for Adverum Biotechnologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VNDA
    Vanda Pharmaceuticals
    1.36x -- $50M -$29.5M
    ADVM
    Adverum Biotechnologies
    -- -- $1M -$47M
  • Which has Higher Returns VNDA or NBY?

    NovaBay Pharmaceuticals has a net margin of -58.94% compared to Vanda Pharmaceuticals's net margin of -49.65%. Vanda Pharmaceuticals's return on equity of -8.26% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    VNDA
    Vanda Pharmaceuticals
    92.96% -$0.50 $511.4M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About VNDA or NBY?

    Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 170.66%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.57%. Given that Vanda Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Vanda Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VNDA
    Vanda Pharmaceuticals
    1 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is VNDA or NBY More Risky?

    Vanda Pharmaceuticals has a beta of 0.683, which suggesting that the stock is 31.678% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock VNDA or NBY?

    Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VNDA or NBY?

    Vanda Pharmaceuticals quarterly revenues are $50M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vanda Pharmaceuticals's net income of -$29.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.36x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VNDA
    Vanda Pharmaceuticals
    1.36x -- $50M -$29.5M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns VNDA or NNVC?

    Nanoviricides has a net margin of -58.94% compared to Vanda Pharmaceuticals's net margin of --. Vanda Pharmaceuticals's return on equity of -8.26% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VNDA
    Vanda Pharmaceuticals
    92.96% -$0.50 $511.4M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About VNDA or NNVC?

    Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 170.66%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 364.29%. Given that Nanoviricides has higher upside potential than Vanda Pharmaceuticals, analysts believe Nanoviricides is more attractive than Vanda Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VNDA
    Vanda Pharmaceuticals
    1 1 0
    NNVC
    Nanoviricides
    0 0 0
  • Is VNDA or NNVC More Risky?

    Vanda Pharmaceuticals has a beta of 0.683, which suggesting that the stock is 31.678% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock VNDA or NNVC?

    Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VNDA or NNVC?

    Vanda Pharmaceuticals quarterly revenues are $50M, which are larger than Nanoviricides quarterly revenues of --. Vanda Pharmaceuticals's net income of -$29.5M is lower than Nanoviricides's net income of -$2.2M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.36x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VNDA
    Vanda Pharmaceuticals
    1.36x -- $50M -$29.5M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns VNDA or OGEN?

    Oragenics has a net margin of -58.94% compared to Vanda Pharmaceuticals's net margin of --. Vanda Pharmaceuticals's return on equity of -8.26% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VNDA
    Vanda Pharmaceuticals
    92.96% -$0.50 $511.4M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About VNDA or OGEN?

    Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 170.66%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1835.68%. Given that Oragenics has higher upside potential than Vanda Pharmaceuticals, analysts believe Oragenics is more attractive than Vanda Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VNDA
    Vanda Pharmaceuticals
    1 1 0
    OGEN
    Oragenics
    0 1 0
  • Is VNDA or OGEN More Risky?

    Vanda Pharmaceuticals has a beta of 0.683, which suggesting that the stock is 31.678% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock VNDA or OGEN?

    Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VNDA or OGEN?

    Vanda Pharmaceuticals quarterly revenues are $50M, which are larger than Oragenics quarterly revenues of --. Vanda Pharmaceuticals's net income of -$29.5M is lower than Oragenics's net income of -$2.2M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.36x versus 0.50x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VNDA
    Vanda Pharmaceuticals
    1.36x -- $50M -$29.5M
    OGEN
    Oragenics
    0.50x -- -- -$2.2M
  • Which has Higher Returns VNDA or TOVX?

    Theriva Biologics has a net margin of -58.94% compared to Vanda Pharmaceuticals's net margin of --. Vanda Pharmaceuticals's return on equity of -8.26% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VNDA
    Vanda Pharmaceuticals
    92.96% -$0.50 $511.4M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About VNDA or TOVX?

    Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 170.66%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1498.17%. Given that Theriva Biologics has higher upside potential than Vanda Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Vanda Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VNDA
    Vanda Pharmaceuticals
    1 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is VNDA or TOVX More Risky?

    Vanda Pharmaceuticals has a beta of 0.683, which suggesting that the stock is 31.678% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock VNDA or TOVX?

    Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VNDA or TOVX?

    Vanda Pharmaceuticals quarterly revenues are $50M, which are larger than Theriva Biologics quarterly revenues of --. Vanda Pharmaceuticals's net income of -$29.5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.36x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VNDA
    Vanda Pharmaceuticals
    1.36x -- $50M -$29.5M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 52x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
65
AEVA alert for Jul 3

Aeva Technologies [AEVA] is up 7.78% over the past day.

Sell
44
PRGS alert for Jul 2

Progress Software [PRGS] is down 2.94% over the past day.

Sell
46
NAIL alert for Jul 3

Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 3.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock